Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden proposed expanding ...

Shares of Eli Lilly & Co. ($LLY) and Novo Nordisk A/S ($NVO) climbed in Tuesday’s premarket trading after the Biden ...

Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' ...

Investors were excited as U.S. President Joe Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare ...

Shares of Novo Nordisk jumped 1.3% after President Biden proposed expanding Medicare and Medicaid coverage for weight-loss ...

and Eli Lilly's (NYSE: LLY) Mounjaro and Zepbound. Below, I'll dig into which pharmaceutical stock I think is the better buy ...

In the past two decades, healthcare giants such as Novo Nordisk (NVO) and Eli Lilly & Co. (LLY) have delivered substantial returns to shareholders. While Eli Lilly stock is up 1,751% over this ...

A new investigation found that such medicines can reduce the risk of Alzheimer's. While this new opportunity will take some time to cook before it's ready to delight shareholders, one of the two ...

But in the last few years, Eli Lilly was a great investment — mostly due to the success of Mounjaro and Zepbound. Nevertheless, the stock seems expensive — also when compared to Novo Nordisk ...

(Bloomberg) -- Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs. Analysts expect the Danish company to start catching up.